AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase II trial.
In the IMGN853-0420 study (NCT05456685), Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC), was investigated in combination with carboplatin, followed by maintenance treatment with Elahere monotherapy, in patients with folate receptor alpha (FRα)-expressing, recurrent PSOC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
By the end of the induction phase, confirmed ORR was 62.7% in the FRα ≥50% subgroup and 62.4% in the overall population.
81% of the 125 enrolled patients showed no disease progression and continued treatment with Elahere alone. Among patients who transitioned to Elahere monotherapy, ORR was 68%.
Median duration of response (DoR) was 11.2 months across the overall population. The safety profile of Elahere remained consistent with previous studies.
Dr Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumour and haematology at AbbVie, said: “Despite being considered chemotherapy-responsive, PSOC remains challenging to treat. With each recurrence, responses to standard platinum-based chemotherapy often diminish, and patients may experience cumulative toxicities.”
Data from the trial was presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting, which took place in San Juan, Puerto Rico, between 10 and 13 April 2026.
AbbVie is running a Phase III trial (NCT05445778) of Elahere in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-expressing PSOC.
Elahere gained US Food and Drug Administration (FDA) approval for use in platinum-resistant ovarian cancer (PROC) in March 2024 and in November of the same year from the European Commission (EC).
GlobalData analysis predicts that Elahere will generate sales of $2.6bn in 2032. GlobalData is the parent company of Clinical Trials Arena.
The value of the ovarian cancer market for the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan) is projected to reach a valuation of $4.1bn in 2032, up from $3.3bn in 2022, according to GlobalData.
